文献速递中毒与环境急症消化、代谢与肾脏急症

硝西泮类物质相关死亡被低估了吗?来自大鼠体内与离体研究及验尸官报告死亡的药物流行病学分析

Is nitazene-related mortality underestimated? Findings from an in vivo and ex vivo rat study and pharmacoepidemiological analysis of coroner-reported deaths.
PubMed 文献 · Clin Toxicol (Phila) · 2026-02-08
一句话结论大鼠模型显示硝西泮类物质在死后血样中不稳定,验尸官数据提示2023年英格兰、威尔士和北爱尔兰硝西泮类相关死亡大幅增加,可能被低估。

该研究结合大鼠体内/离体实验与区域验尸官数据,探讨硝西泮类物质死后稳定性及死亡趋势。12只麻醉Wistar大鼠静脉注射美托尼他嗪、N-去乙基异托尼他嗪或N-吡咯烷基依托尼他嗪,8只在给药后15分钟未发生心肺骤停时被处死,血尿样本在4°C冷藏一周后复测。结果显示死后第7天冷藏一个月的血样中仅剩少量硝西泮类物质。伯明翰与索利霍尔姆验尸区2023年非硝西泮类药物死亡较2019-2022年上升33%(预测107例,实际142例)。截至2025年3月,国家物质使用死亡监测项目报告285例检出硝西泮类的死亡,2023年增至131例,验尸官认定90%(256/285)的死亡由硝西泮类所致。作者认为死亡可能因死后不稳定而被低估,需紧急公共卫生行动。

要点

  • 大鼠死后第7天冷藏一个月的血样中仅剩少量硝西泮类物质,提示死后血样检测可能低估暴露。
  • 伯明翰与索利霍尔姆2023年非硝西泮类药物死亡142例,较2019-2022年预测的107例上升33%。
  • 截至2025年3月,国家监测项目报告285例检出硝西泮类的死亡,2023年131例,2021年23例,2022年15例。
  • 检出的12种硝西泮类中,主要品种随时间变化:2021年为异托尼他嗪,2022年为N-吡咯烷基依托尼他嗪,2023年为N-去乙基异托尼他嗪。
  • 验尸官认定90%(256/285)的硝西泮类检出死亡中该物质为死因。

适用人群与场景

  • 大鼠实验:12只麻醉Wistar大鼠,静脉给予美托尼他嗪、N-去乙基异托尼他嗪或N-吡咯烷基依托尼他嗪。
  • 药物流行病学分析:伯明翰与索利霍尔姆验尸区2019-2023年所有死亡,以及国家物质使用死亡监测项目截至2025年3月报告的硝西泮类检出死亡。

研究设计与关键结果

  • 大鼠体内/离体研究:8只大鼠在给药后15分钟未发生心肺骤停时被处死,血尿样本立即冻存于-80°C;死后第7天冷藏(4°C)一周的血样中仅剩少量硝西泮类物质。
  • 药物流行病学:伯明翰与索利霍尔姆2023年非硝西泮类药物死亡142例,较2019-2022年指数平滑模型预测的107例上升33%。
  • 截至2025年3月,国家物质使用死亡监测项目报告285例检出硝西泮类的死亡,2021年23例,2022年15例,2023年131例。
  • 共检出12种硝西泮类,主要品种2021年为异托尼他嗪,2022年为N-吡咯烷基依托尼他嗪,2023年为N-去乙基异托尼他嗪。
  • 验尸官认定硝西泮类为死因的占90%(256/285)。

证据类型、等级与局限

  • 证据类型:大鼠体内/离体实验与药物流行病学分析(描述性分析及指数平滑模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为硝西泮类相关死亡在英格兰、威尔士和北爱尔兰有所增加,且可能因死后不稳定而被低估。
  • 作者认为需要紧急公共卫生行动以减少硝西泮类相关危害。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Nitazenes are potent synthetic opioids. Following reports questioning their post-mortem stability, nitazene-related deaths may have been underestimated in the United Kingdom. We investigated this using a rat model and regional coronial data, and also present national pharmacoepidemiologic trends in nitazene-related deaths.

METHOD: In vivo/ex vivo study: Anaesthetised Wistar rats (n = 12) received intravenous nitazene (metonitazene, N-desethyl isotonitazene, or N-pyrrolidino etonitazene). Rats were euthanised 15 min post-administration if cardiorespiratory arrest had not already occurred (n = 8). Blood and urine were collected, with repeat blood samples taken following cadaver refrigeration (4 °C) for one week. All samples were immediately frozen (-80 °C). Upon defrosting, half were analysed immediately by liquid chromatography tandem mass spectroscopy with half stored at 4 °C for 1 month before analysis.

PHARMACOEPIDEMIOLOGY: Nitazene deaths were extracted from the National Programme on Substance Use Mortality in March 2025 along with all deaths from the Birmingham & Solihull coronial area (2019-2023). Descriptive analyses were conducted along with exponential smoothing models to compare observed and forecasted deaths in Birmingham & Solihull in 2023.

RESULTS: In vivo/ex vivo study: A small fraction of the nitazene detected in the immediate post-mortem blood sample remained in the post-mortem day 7 blood sample that had been refrigerated for 1 month.

PHARMACOEPIDEMIOLOGY: In Birmingham and Solihull, non-nitazene drug deaths rose 33% in 2023 compared to 2019-2022 (predicted n = 107, actual n = 142). By March 2025, 285 deaths with nitazene detections were reported to the National Programme on Substance Use Mortality, with small clusters in 2021 (n = 23) and 2022 (n = 15) before markedly increasing in 2023 (n = 131). Twelve nitazenes were detected with the predominant nitazene shifting over time (2021: isotonitazene; 2022: N-pyrrolidino etonitazene; 2023: N-desethyl isotonitazene). Coroners deemed nitazenes causative in 90% of cases (n = 256/285).

CONCLUSIONS: Nitazene-related deaths have increased in England, Wales, and Northern Ireland, and may have been underestimated due to post-mortem instability. Urgent public health action is required to reduce nitazene-related harms.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Chen S, Aldabergenov D, Alotaibi KS, et al. Is nitazene-related mortality underestimated? Findings from an in vivo and ex vivo rat study and pharmacoepidemiological analysis of coroner-reported deaths. Clin Toxicol (Phila). 2026. PMID: 41655595. doi:10.1080/15563650.2025.2601141

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。